Apnimed Reports Third Quarter 2026 Financial Results and Provides Corporate Update
New Drug Application (“NDA”) for AD109, with a proposed proprietary name Oxnimbi™ (aroxybutynin and
New Drug Application (“NDA”) for AD109, with a proposed proprietary name Oxnimbi™ (aroxybutynin and